NDAURETERALSOLUTION
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENO-30 is a diatrizoate meglumine solution administered via ureteral route as a radiographic contrast agent for diagnostic imaging procedures. This small-molecule contrast medium enhances visualization of the urinary system during radiological examinations. The drug works by absorbing X-rays to create contrast in targeted anatomical structures.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect downsizing or transition planning within the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENO-30 offers limited career advancement due to its mature, declining lifecycle and zero linked job openings. This role is best suited for professionals seeking stable, low-stress positions in legacy product management rather than high-growth opportunities.
Brand ManagerField Sales Representative
Worked on RENO-30 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.